Telemedicine

Teladoc Health Launches Telemedicine Service in Canada, Expanding Portfolio of Available Healthcare Solutions. Canadians to benefit from access to anytime, anywhere high-quality physician care

TORONTO, ON, March 28, 2019 –Teladoc Health (NYSE: TDOC), the global leader in virtual care, announces today the launch of Teladoc Telemedicine Services, the first-of-its-kind offering to provide Canadians with 24×7 access to convenient, high-quality medical care regardless of their location across the country or in the U.S. The new service addresses head-on the healthcare access issues Canadians are facing in terms of overcrowded emergency rooms, physician shortages, and long wait times, which have been persistent in rural and urban areas alike. It also supports efforts of employers to address illness-related productivity issues… READ MORE

double exposure image of virtual human 3dillustration on blue circuit board background represent artificial 
intelligence AI technology

Cardinal Analytx Bounds into Next Growth Phase with Former DecisionView CEO Linda Hand at Helm

Cardinal Analytx Solutions, a developer of advanced machine learning solutions for improving healthcare while reducing costs by predicting impending medical conditions, today announced it has hired healthcare veteran Linda T. Hand as CEO to lead the company through its next phase of growth. Formerly president and CEO of DecisionView, Hand joins Cardinal Analytx at a pivotal time of significant company momentum, with two new advisors also coming aboard….  READ MORE

vitals

Vitals Announces Company Name Change to Sapphire Digital

FEBRUARY 20, 2019 – LYNDHURST, N.J. – Vitals announces that we are changing our name to Sapphire Digital. The new name reflects our leadership in providing a full omnichannel digital engagement and shopping platform for consumers, employers and health plans to impact the cycle of high-cost health care…. READ MORE

abide

Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s

  • Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the potential to deliver unprecedented compounds across a broad range of central nervous system (CNS) indications
  • Abide’s lead product ABX 1431 is a first-in-class inhibitor of monoacylglycerol lipase (MGLL), modulating the endocannabinoid system. ABX-1431 is in clinical development for Tourette’s  (exploratory phase IIa) and neuropathic pain (phase I)
  • Lundbeck to acquire Abide for USD 250 million in upfront payment and with additional development and sales milestones

Valby, Denmark, San Diego, USA, 6 May 2019 – H. Lundbeck A/S (Lundbeck) and Abide Therapeutics, Inc. (Abide) today announced signing of a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up to USD 150 million (approximately DKK 1 billion). This acquisition provides Lundbeck a novel discovery platform and a U.S.-based research hub…READ MORE

Scroll to top